Clinical Effect of Xuezhikang Capsule Combined with Rosuvastatin Calcium Tablets in the Treatment of Mutual Obstruction of Phlegm and Blood Stasis Hyperlipidemia
LI Linglu
XU Meixia
YANG Xuemei
Abstract：Objective To study the clinical effect of Xuezhikang capsule combined with rosuvastatin calcium tablets on mutual obstruction of phlegm and blood stasis hyperlipidemia.Methods From January 2022 to June 2023,80 patients with mutual obstruction of phlegm and blood stasis hyperlipidemia in Fumin Road Street Community Health Service Center were randomly divided into a control group and a study group,with 40 cases in each group.The control group was treated with rosuvastatin calcium tablets,while the study group was treated with Xuezhikang capsule on the basis of rosuvastatin calcium tablets.The blood lipid level,hemorheology and inflammatory factors were compared between the two qroups.Results After treatment,the levels of total cholesterol,triglycerides,low-density lipoprotein,apolipoprotein A,and apolipoprotein B in the study group were lower than those in the control group,while the high-density lipoprotein was higher than the control group(P<0.05).The hematocrit,fibrinogen,plasma viscosity,maximum platelet aggregation rate,whole blood high shear viscosity,and whole blood low shear viscosity in the study group were lower than those of the control group(P<0.05).The levels of interleukin-6,interleukin-1β,interleukin-18,intercellular adhesion molecule-1,high-sensitivity C-reactive protein,and tumor necrosis factor-α in the study group were all lower than those in the control group(P<0.05).Conclusion The combination of xuezhikang capsules and rosuvastatin calcium tablets can effectively reduce blood lipid levels,improve blood rheology and regulate inflammatory factor levels in the treatment of mutual obstruction of phlegm and blood stasis hyperlipidemia.
Keywords：HyperlipidemiaMutual Obstruction of Phlegm and Blood Stasis TypeXuezhikang CapsuleRosuvastatin Calcium Tablet
Publication Date：2025-04-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 51-54,58 )